Evoke Pharma (DB:EV0) - Aandelenkoers, Nieuws & Analyse

EV0 Overzicht aandelen

EV0 fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 117.22% per jaar groeien

De winst is de afgelopen 5 jaar met 5% per jaar gegroeid

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Heeft geen betekenisvolle marktkapitalisatie ( €6M )

Aandelen zijn zeer illiquide

Evoke Pharma, Inc. Concurrenten

Biofrontera

XTRA:B8FK

€15.8m

MPH Health Care

DB:93M1

€102.8m

SynBiotic

DUSE:SBX

€27.9m

Redx Pharma

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Evoke Pharma
Historische aandelenkoersen
Huidige aandelenkoers	US$3.97
52 Week Hoogtepunt	US$15.00
52 Week Laag	US$0.33
Bèta	0.38
11 maand verandering	0%
3 maanden verandering	-2.71%
1 Jaar Verandering	-70.46%
33 jaar verandering	-97.46%
5 jaar verandering	-96.68%
Verandering sinds IPO	-99.69%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	EV0	DE Pharmaceuticals	DE Markt
7D	0%	-0.3%	0.8%
1Y	-70.5%	-18.3%	8.6%

Rendement versus industrie: EV0 presteerde slechter dan de German Pharmaceuticals -sector, die het afgelopen jaar een rendement van -18.3 % opleverde.

Rendement versus markt: EV0 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.6 % opleverde.

Prijsvolatiliteit

Is EV0's price volatile compared to industry and market?
EV0 volatility
EV0 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: De aandelenkoers van EV0 is de afgelopen 3 maanden volatiel geweest.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van EV0 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2007	4	Matt D'Onofrio	www.evokepharma.com

Evoke Pharma, Inc. is een gespecialiseerd farmaceutisch bedrijf dat zich voornamelijk toelegt op de ontwikkeling en commercialisering van geneesmiddelen voor de behandeling van gastro-enterologische aandoeningen en ziekten. Het biedt Gimoti aan, een metoclopramide neusspray voor de behandeling van symptomen die gepaard gaan met acute en terugkerende diabetische gastroparese bij volwassenen. Het bedrijf verkoopt zijn producten aan gastro-enterologen, specialisten interne geneeskunde, huisartsen en geselecteerde zorgverleners.

Evoke Pharma, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Evoke Pharma zich tot de beurswaarde?
EV0 fundamentele statistieken
Marktkapitalisatie	€5.36m
Inkomsten(TTM)	-€6.04m
Inkomsten(TTM)	€6.96m

0.8x

P/S-verhouding

-0.9x

Koers/Winstverhouding

Is EV0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
EV0 resultatenrekening (TTM)
Inkomsten	US$7.53m
Kosten van inkomsten	US$227.94k
Brutowinst	US$7.30m
Overige uitgaven	US$13.83m
Inkomsten	-US$6.53m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-7.97
Brutomarge	96.97%
Nettowinstmarge	-86.75%
Schuld/Eigen Vermogen Verhouding	187.6%

Hoe presteerde EV0 op de lange termijn?

Bekijk historische prestaties en vergelijking

EV0 Overzicht aandelen

Beloningen

Risicoanalyse

Evoke Pharma, Inc. Concurrenten

XTRA:B8FK

€15.8m

DB:93M1

€102.8m

DUSE:SBX

€27.9m

DB:0RX

€65.0m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024

Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million.

Second quarter 2024 earnings released: US$0.93 loss per share (vs US$6.71 loss in 2Q 2023)

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Recent updates

Evoke Pharma, Inc. Revises Sales Guidance for the Year 2024

Evoke Pharma, Inc. Appoints Benjamin Smeal to Serve as Class II Director

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $1.921957 million.

Second quarter 2024 earnings released: US$0.93 loss per share (vs US$6.71 loss in 2Q 2023)

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma, Inc. Revises Earnings Guidance for the Year 2024

Evoke Pharma Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement

First quarter 2024 earnings released: US$0.17 loss per share (vs US$0.67 loss in 1Q 2023)

Evoke Pharma, Inc., Annual General Meeting, May 22, 2024

Evoke Pharma, Inc. Announces Chief Executive Officer Changes as of March 31, 2024

Evoke Pharma, Inc. Provides Earnings Guidance for 2024

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Evoke Pharma Receives Letter from Nasdaq Regarding Non-Compliance with Nasdaq’s Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Under Nasdaq Listing Rule 5550(a)(2)

New major risk - Shareholder dilution

Evoke Pharma, Inc. has completed a Follow-on Equity Offering.

Evoke Pharma Announces Update on Non-Compliance Notice from Nasdaq

Evoke Pharma Receives Notice from Nasdaq

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $15 million.

Third quarter 2023 earnings released: US$0.51 loss per share (vs US$0.60 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Evoke Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $30 million.

Evoke Pharma, Inc. Provides Summary of Real-World Data on the Positive Impact of GIMOTI

Evoke Pharma, Inc. Receives Notice of Allowance from U.S. Patent and Trademark Office for GIMOTI

Second quarter 2023 earnings released: US$0.56 loss per share (vs US$0.71 loss in 2Q 2022)

Nasdaq Grants Evoke Pharma an Extension Until November 20, 2023 to Regain Compliance

Evoke Pharma Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

First quarter 2023 earnings released: US$0.67 loss per share (vs US$0.80 loss in 1Q 2022)

Full year 2022 earnings released: US$2.62 loss per share (vs US$3.18 loss in FY 2021)

Evoke Pharma, Inc. Announces Executive Changes

Evoke Pharma, Inc. Announces Teva Ends Pursuit of Paragraph IV ANDA Against Gimoti

Evoke Pharma Announces Acceptance of an Abstract at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting 2023

Third quarter 2022 earnings released: US$0.60 loss per share (vs US$0.73 loss in 3Q 2021)

Evoke Pharma, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Evoke Pharma, Inc. announces United States Patent and Trademark Office Issues Notice of Allowance for the its Product, GIMOTI® (Metoclopramide) Nasal Spray

Second quarter 2022 earnings released: US$0.71 loss per share (vs US$0.85 loss in 2Q 2021)

Evoke Pharma, Inc. to Report Q2, 2022 Results on Aug 10, 2022

Evoke Pharma, Inc. Expands IP Portfolio with Addition of Canadian Patent Covering GIMOTI Method of Use

Evoke Pharma Announces Approval of GIMOTI® to Florida State Medicaid Program

Evoke Pharma Regains Compliance with Nasdaq Listing Requirements and Provides Financial Update

Evoke Pharma, Inc. Announces Real-World Data Analysis Reveals Lower Risk of Tardive Dyskinesia with Metoclopramide Than Previously Reported

Evoke Pharma, Inc. Announces Positive Findings from the First Patient-Centered Survey Related to GIMOTI®

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q1, 2022 Results on May 10, 2022

Evoke Pharma Granted FDA Market Exclusivity for Gimoti®

Evoke Pharma, Inc. Announces Approval of GIMOTI to the Texas Medicaid Preferred Drug List

Insufficient new directors

No longer forecast to breakeven

Evoke Pharma, Inc. to Report Q4, 2021 Results on Mar 08, 2022

Evoke Pharma, Inc. Announces Positive Outcomes from an Additional Research Study Conducted for GIMOTI

Evoke Pharma, Inc. Announces Positive Findings from A Second Market Research Study Conducted for Gimoti® (Metoclopramide) Nasal Spray

Evoke Pharma, Inc. Announces the Launch of Wave 1 of an Innovative Social Media Campaign to Reach Patients Directly with Education About Diabetic Gastroparesis

Independent Director has left the company

No longer forecast to breakeven

Revenue misses expectations

Evoke Pharma, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day low: €2.00

Evoke Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million.

Evoke Pharma, Inc. Announces, Through its Marketing Partner, Eversana Life Science Services, LLC, Conducted an ATU (Awareness, Trial, and Usage) Study, Quantitative Survey to Measure Physician Awareness, Trial, and Product Usage, for GIMOTI